PRODUCT APPROVALS WOULD BE EXEMPT FROM COST/BENEFIT ANALYSIS OF RISK REDUCTIONS UNDER REP. OXLEY AMENDMENT TO HR 9; SENATE BILL SIMILARLY WORDED
Executive Summary
Product approvals would be exempted from cost/benefit analyses of risk reduction under a substitute amendment to Title III of the "Job Creation and Wage Enhancement Act" (HR 9) offered by House Commerce/Commerce & Trade and Health Subcommittee Chairmen Oxley (R-Ohio) and Bilirakis (R-Fla.) during a full committee markup Feb. 8.